Calcitonin gene-related peptide (receptor) antibodies: an exciting avenue for migraine treatment
- PMID: 29471874
- PMCID: PMC5824555
- DOI: 10.1186/s13073-018-0524-7
Calcitonin gene-related peptide (receptor) antibodies: an exciting avenue for migraine treatment
Abstract
Specific prophylactic migraine treatments are urgently needed because of the unmet needs of many migraine patients. Antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor have recently shown efficacy in episodic and chronic migraine and will be available soon.
Conflict of interest statement
Competing interests
AMVDB has obtained research grants from Amgen/Novartis and Lilly. GMT reports consultancy support from Novartis and Lilly. AMJMvdM declares that he has no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
